Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4⁺ T cell interleukin-2 secretion

References

• Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the ‘high-hanging fruit’. Nat Rev Drug Discov. 2018;17(3):197–9. doi:10.1038/nrd.2017.227.
   PubMed Web of Science ®Google Scholar
• Jawa V, Terry F, Gokemeijer J, Mitra-Kaushik S, Roberts BJ, Tourdot S, De Groot AS. T-Cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation-updated consensus and review 2020. Front Immunol. 2020;11:1301. doi:10.3389/fimmu.2020.01301.
   PubMed Web of Science ®Google Scholar
• Smith A, Manoli H, Jaw S, Frutoz K, Epstein AL, Khawli LA, Theil F-P. Unraveling the effect of immunogenicity on the PK/PD, efficacy, and safety of therapeutic proteins. J Immunol Res. 2016;2016:1–9. doi:10.1155/2016/2342187.
   Web of Science ®Google Scholar
• Ridker PM, Tardif J-C, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med. 2017;376(16):1517–26. doi:10.1056/NEJMoa1614062.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182–212. doi:10.1080/19420862.2016.1268307.
   PubMed Web of Science ®Google Scholar
• Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67(2):95–106. doi:10.1016/j.molimm.2015.01.003.
   PubMed Web of Science ®Google Scholar
• Rosenberg AS, Sauna ZE. Immunogenicity assessment during the development of protein therapeutics. J Pharm Pharmacol. 2018;70(5):584–94. doi:10.1111/jphp.12810.
   PubMed Web of Science ®Google Scholar
• Barbosa MD, Vielmetter J, Chu S, Smith DD, Jacinto J. Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicity. Clinical Immunology. 2006;118(1):42–50. doi:10.1016/j.clim.2005.08.017.
   PubMed Web of Science ®Google Scholar
• Sekiguchi N, Kubo C, Takahashi A, Muraoka K, Takeiri A, Ito S, Yano M, Mimoto F, Maeda A, Iwayanagi Y, et al. MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity. MAbs. 2018;10(8):1168–81. doi:10.1080/19420862.2018.1518888.
   PubMed Web of Science ®Google Scholar
• Yeung VP, Chang J, Miller J, Barnett C, Stickler M, Harding FA. Elimination of an immunodominant CD4+ T cell epitope in human IFN-β does not result in an in vivo response directed at the subdominant epitope. The Journal Of Immunology. 2004;172(11):6658–65. doi:10.4049/jimmunol.172.11.6658.
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010;2(3):256–65. doi:10.4161/mabs.2.3.11641.
   PubMed Web of Science ®Google Scholar
• Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson S, Chirmule N, Jawa V. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clinical Immunology. 2010;137(1):5–14. doi:10.1016/j.clim.2010.06.018.
   PubMed Web of Science ®Google Scholar
• Moser JM, Sassano ER, Leistritz DC, Eatrides JM, Phogat S, Koff W, Drake DR. Optimization of a dendritic cell-based assay for the in vitro priming of naïve human CD4+ T cells. Journal Of Immunological Methods. 2010;353(1–2):8–19. doi:10.1016/j.jim.2009.11.006.
   PubMed Web of Science ®Google Scholar
• Stickler M, Rochanayon N, Razo OJ, Mucha J, Gebel W, Faravashi N, Chin R, Holmes S, Harding FA. An in vitro human cell-based assay to rank the relative immunogenicity of proteins. Toxicol Sci. 2004;77(2):280–89. doi:10.1093/toxsci/kfh021.
   PubMed Web of Science ®Google Scholar
• Geiger R, Duhen T, Lanzavecchia A, Sallusto F. Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J Exp Med. 2009;206(7):1525–34. doi:10.1084/jem.20090504.
   PubMed Web of Science ®Google Scholar
• Delluc S, Ravot G, Maillere B. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. FASEB J. 2011;25(6):2040–48. doi:10.1096/fj.10-173872.
   PubMed Web of Science ®Google Scholar
• Schultz HS, Reedtz-Runge SL, Bäckström BT, Lamberth K, Pedersen CR, Kvarnhammar AM. Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell: PBMC assay. PLoS One. 2017;12(5):e0178544. doi:10.1371/journal.pone.0178544.
   PubMed Web of Science ®Google Scholar
• Joubert MK, Deshpande M, Yang J, Reynolds H, Bryson C, Fogg M, Baker MP, Herskovitz J, Goletz TJ, Zhou L, et al. Use of in vitro assays to assess immunogenicity risk of antibody-based biotherapeutics. PLoS One. 2016;11(8):e0159328. doi:10.1371/journal.pone.0159328.
   PubMed Web of Science ®Google Scholar
• Ito S, Ikuno T, Mishima M, Yano M, Hara T, Kuramochi T, Sampei Z, Wakabayashi T, Tabo M, Chiba S, et al. In vitro human helper T-cell assay to screen antibody drug candidates for immunogenicity. J Immunotoxicol. 2019;16(1):125–32. doi:10.1080/1547691X.2019.1604586.
   PubMed Web of Science ®Google Scholar
• Cohen S, Myneni S, Batt A, Guerrero J, Brumm J, Chung S. Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells. MAbs. 2021;13(1):1898831. doi:10.1080/19420862.2021.1898831.
   PubMed Web of Science ®Google Scholar
• Mempel TR, Henrickson SE, Von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature. 2004;427(6970):154–59. doi:10.1038/nature02238.
   PubMed Web of Science ®Google Scholar
• Wuest SC, Edwan JH, Martin JF, Han S, Perry JSA, Cartagena CM, Matsuura E, Maric D, Waldmann TA, Bielekova B. A role for interleukin-2 trans-presentation in dendritic cell–mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med. 2011;17(5):604–09. doi:10.1038/nm.2365.
   PubMed Web of Science ®Google Scholar
• Walsh RE, Lannan M, Wen Y, Wang X, Moreland CA, Willency J, Knierman MD, Spindler L, Liu L, Zeng W, et al. Post-hoc assessment of the immunogenicity of three antibodies reveals distinct immune stimulatory mechanisms. MAbs. 2020;12(1):1764829. doi:10.1080/19420862.2020.1764829.
   PubMed Web of Science ®Google Scholar
• Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfeld J, Sasso EH. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131:308–16. doi:10.1016/j.clim.2009.01.002.
   PubMed Web of Science ®Google Scholar
• Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and α v β 3 integrins. Circulation. 1998;98(11):1085–91. doi:10.1161/01.cir.98.11.1085.
   PubMed Web of Science ®Google Scholar
• Chouinard L, Felx M, Mellal N, Varela A, Mann P, Jolette J, Samadfam R, Smith SY, Locher K, Buntich S, et al. Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study. Regul Toxicol Pharmacol. 2016;81:212–22. doi:10.1016/j.yrtph.2016.08.010.
   PubMed Web of Science ®Google Scholar
• Recker RR, Benson CT, Matsumoto T, Bolognese MA, Robins DA, Alam J, Chiang AY, Hu L, Krege JH, Sowa H, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015;30(2):216–24. doi:10.1002/jbmr.2351.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Pal S, Chattopadhyay N. Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: a critical assessment of the mechanism of action. Eur J Pharmacol. 2018;826:39–47. doi:10.1016/j.ejphar.2018.02.028.
   PubMed Web of Science ®Google Scholar
• Ritter G, Cohen LS, Williams C, Richards EC, Old LJ, Welt S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res. 2001;61:6851–59.
   PubMed Web of Science ®Google Scholar
• Welt S, Ritter G, Williams Jr C, Cohen LS, John M, Jungbluth A, Richards EA, Old LJ, Kemeny NE. Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res. 2003;9:1338–46.
   PubMed Web of Science ®Google Scholar
• King DJ, Antoniw P, Owens RJ, Adair JR, Haines A, Farnsworth A, Finney H, Lawson A, Lyons A, Baker TS, et al. Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer. 1995;72(6):1364–72. doi:10.1038/bjc.1995.516.
   PubMed Web of Science ®Google Scholar
• Liang H, Chaparro-Riggers J, Strop P, Geng T, Sutton JE, Tsai D, Bai L, Abdiche Y, Dilley J, Yu J, et al. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther. 2012;340(2):228–36. doi:10.1124/jpet.111.187419.
   PubMed Web of Science ®Google Scholar
• Mizuno H, Nakanishi Y, Ishii N, Sarai A, Kitada K. A signature-based method for indexing cell cycle phase distribution from microarray profiles. BMC Genom. 2009;10(1):137. doi:10.1186/1471-2164-10-137.
   PubMedGoogle Scholar
• Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, Yoshihashi K, Okuyama-Nishida Y, Saito H, Tsunoda H, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia a model. Nat Med. 2012;18(10):1570–74. doi:10.1038/nm.2942.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, et al. Emicizumab prophylaxis in hemophilia a with inhibitors. N Engl J Med. 2017;377(9):809–18. doi:10.1056/NEJMoa1703068.
   PubMed Web of Science ®Google Scholar
• Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013;8(2):e57479. doi:10.1371/journal.pone.0057479.
   PubMed Web of Science ®Google Scholar
• Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180–90. doi:10.1038/nri3156.
   PubMed Web of Science ®Google Scholar
• Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539–51. doi:10.1056/NEJMra1104650.
   PubMed Web of Science ®Google Scholar
• Gorovits B. Current considerations for immunoglobulin isotype characterization of antibody response against biotherapeutics. AAPS J. 2020;22(6):144. doi:10.1208/s12248-020-00530-4.
   PubMed Web of Science ®Google Scholar
• Krishna M, Nadler SG. Immunogenicity to biotherapeutics - the role of anti-drug immune complexes. Front Immunol. 2016;7:21. doi:10.3389/fimmu.2016.00021.
   PubMed Web of Science ®Google Scholar
• Weeraratne DK, Kuck AJ, Chirmule N, Mytych DT. Measurement of anti-erythropoiesis-stimulating agent IgG4 antibody as an indicator of antibody-mediated pure red cell aplasia. Clin Vaccine Immunol. 2013;20(1):46–51. doi:10.1128/CVI.00435-12.
   PubMedGoogle Scholar
• Whelan SF, Hofbauer CJ, Horling FM, Allacher P, Wolfsegger MJ, Oldenburg J, Male C, Windyga J, Tiede A, Schwarz HP, et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia a patients. Blood. 2013;121(6):1039–48. doi:10.1182/blood-2012-07-444877.
   PubMed Web of Science ®Google Scholar
• Quarmby V, Phung QT, Lill JR. MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arena. Expert Rev Proteomics. 2018;15(9):733–48. doi:10.1080/14789450.2018.1521279.
   PubMed Web of Science ®Google Scholar
• Wen Y, Cahya S, Zeng W, Lin J, Wang X, Liu L, Malherbe L, Siegel R, Ferrante A, Kaliyaperumal A, et al. Development of a FRET-Based assay for analysis of mAbs Internalization and processing by dendritic cells in preclinical immunogenicity risk assessment. AAPS J. 2020;22(3):68. doi:10.1208/s12248-020-00444-1.
   PubMed Web of Science ®Google Scholar
• Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci. 2011;100(2):354–87. doi:10.1002/jps.22276.
   PubMed Web of Science ®Google Scholar
• King DJ, Adair J, Owens RJ Humanized antibodies directed against A33 antigen. International Patent, Application No.: PCT/GB93/02529; 1993 filed; http://www.google.co.in/patents/WO1994013805A1?cl=en&hl=ja.
   Google Scholar